Shelby Lane, MD
Radiation Oncology · Memphis, TNNPI 1457814774
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,015, more than ten times the $43 reported in 2021.
Across 66 payments — averaging $24.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$234
- Merck$230
- Boston Scientific$190
- Novartis$120
- Eisai Inc.$110
- Lilly USA, LLC$83
- plus $650 from 21 others
What the payments were for
- Food & beverage$1,616100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 6 | $234 |
| Merck | 10 | $230 |
| Boston Scientific | 2 | $190 |
| Novartis | 6 | $120 |
| Eisai Inc. | 4 | $110 |
| Lilly USA, LLC | 4 | $83 |
| Genentech USA, Inc. | 4 | $67 |
| Geron Corporation | 3 | $57 |
| Sobi, Inc | 3 | $53 |
| Bayer | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Incyte Corporation | 2 | $40 |
| Sun Pharmaceutical Industries Inc. | 2 | $33 |
| Blueprint Medicines Corporation | 1 | $33 |
| Taiho Oncology, Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $29 |
| AVEO Pharmaceuticals, Inc. | 1 | $25 |
| Legend Biotech USA Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Immunocore Limited | 1 | $17 |
| Coherus Oncology, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Iovance Biotherapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SpaceOAR System$186
- DATROWAY$110
How this compares
$1,616 in reported general payments places this provider in the 70th percentile of 115 radiation oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Memphis
- David RobergeMemphis$28K
- Matthew BalloMemphis$25K
- Daniel WakefieldMemphis$9K
- Thomas MerchantMemphis$6K
- David SchwartzMemphis$3K
- Holger GieschenMemphis$1K
- Angela WorthamMemphis$714
- Han-Chih ChangNashville$66K
- Karen WinkfieldNashville$53K
- James GrayNashville$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.